Biotech targeting rare heart mutation with gene therapy scores $11M in Series A haul
While cardiovascular disease is the leading cause of death globally — it is cancer that has benefited most from strides in precision medicine. Now that cardiovascular-specific genetic mutations are being discovered — they are prime targets for genetic therapy. A biotechnology company carved out of research conducted at Temple University is focusing on a mutant gene that is understood to cause a rare heart condition, which can eventually lead to a heart transplant or the use of implanted cardiac assist devices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.